SCHEMBL24254499

SCHEMBL24254499

Cc1ccc(S(=O)(=O)NCc2ccccc2)cc1NC(=O)Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
SLC12A2 P55011 1/20 0.53
SLC12A5 Q9H2X9 1/20 0.53
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
MAPT P10636 2/20 0.51
POLB P06746 1/20 0.51
GLA P06280 1/20 0.49
CTSD P07339 2/20 0.49
VCAM1 P19320 1/20 0.48
ALDH1A1 P00352 2/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA5A P35218 1/20 0.47
CA7 P43166 1/20 0.47
CA5B Q9Y2D0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24254503 0.87 MGAT2 (0.54) LMNAKMT2AMEN1MAPTALDH1A1
SCHEMBL24254488 0.84 KMT2A (0.58) LMNASLC12A2SLC12A5KMT2AMEN1
SCHEMBL26188045 0.82 ALDH1A1 (0.57) LMNAKMT2AMEN1MAPTCTSD
SCHEMBL24254502 0.80 ALDH1A1 (0.66) LMNAKMT2AMEN1MAPTPOLB
SCHEMBL24254494 0.79 EPHX2 (0.55) LMNAMAPTALDH1A1HTTSMN1; SMN2
SCHEMBL24254550 0.78 HPGD (0.46) LMNAKMT2AMEN1MAPTPOLB
SCHEMBL24254585 0.76 HTT (0.74) LMNAKMT2AMEN1MAPTALDH1A1
SCHEMBL24254529 0.76 ALDH1A1 (0.53) LMNAKMT2AMEN1MAPTALDH1A1
SCHEMBL21102237 0.74 CTSD (0.59) LMNAMAPTCTSDALDH1A1HTT
SCHEMBL24254519 0.73 MGAT2 (0.57) LMNAKMT2AMEN1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 LMNA 3727/4885SLC12A2 3772/4885SLC12A5 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.